DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADB183615
Title:
Development of Antibiotic Formulations for Combat Casualty Care
Descriptive Note:
Final rept. 16 Jul 1992-21 Feb 1994
Corporate Author:
SOUTHERN RESEARCH INST BIRMINGHAM AL
Report Date:
1994-03-21
Pagination or Media Count:
63.0
Abstract:
The object of this contract was to develop biodegradable, controlled- release formulations for the local administration of cefamandole and tobramycin. These formulations were designed to prevent infection of wounds resulting from warfare. Under the original scope of the research program we planned to develop two dosage forms for each drug -- microspheres and microbeads. The microsphere formulations, antibiotic spheres less than 1 mm in diameter, were designed for topical administration. The microbead formulations, antibiotic spheres about 5 mm in diameter, were designed for intraosteal administration. On October 18, 1993, the contract for this research program was modified to delete the tobramycin microbead deliverable from the contract requirements. To meet the objective of this research program, we prepared and characterized microsphere and microbead formulations with cefamandole and tobramycin. We developed a cefamandole microsphere formulation that released cefamandole for 28 days in vitro and a cefamandole microbead formulation that released cefamandole for 35 days in vitro. And we developed a tobramycin microsphere formulation that released tobramycin for 35 days in vitro. Samples of these formulations were sent to the U.S. Army Institute of Dental Research USAIDR for in-house evaluation in vivo efficacy. Antibiotic, Tobramycin, Cefamandole, Microspheres, Controlled release, Wound treatment, Microbeads, Osteomyelitis.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
